Mergers, acquisitions, and restructuring - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mergers, acquisitions, and restructuring
A roundup of company moves and positioning from the pharmaceutical and biotechnology industries and contract service providers.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 10

As part of the transaction, which was announced in March 2007, Novartis transferred manufacturing responsibility for Betaseron to Bayer and received a total payment of roughly $200 million for the transfer of production equipment, inventory, and the leasing of buildings at the site.

Bayer will pay Novartis royalties on the net sales of Betaseron manufactured at the Emeryville facilities until the original regulatory filing, development, and supply agreement expires in October 2008.

Bayer will help Novartis submit a regulatory filing for the latter's 250-μg version of interferon beta-1b. If Novartis's drug is approved, Bayer will manufacture the product for Novartis from 2009 onward. In return, Novartis will make royalty payments to Bayer.

Sandwich, UK (Sept. 11)—Pfizer (New York) plans to cease all remaining manufacturing operations at its facility in Sandwich, Kent, United Kingdom. The closure will result in the loss of approximately 420 jobs, phased over the next two years, according to a company release.

The move is part of Pfizer's ongoing efforts to consolidate worldwide manufacturing operations to manage global capacity and demand more efficiently, as well as establish a smaller and more flexible cost base, the company specified.

The Sandwich facility manufactures active pharmaceutical ingredients (APIs) for human and veterinary drugs. Also located at Sandwich are a bioprocess development group, which develops new processes for the manufacture of pharmaceuticals using living (biological) systems, and a process analytical support group, which develops technologies to improve process understanding and control within Pfizer's plants.

A small API development function, comprising around 10–15 roles, will remain at Sandwich to support the development of regulatory starting materials. Site infrastructure services (e.g., provision of utilities and waste management) will also continue at Sandwich.

In January 2005, Pfizer announced a rationalization of manufacturing at Sandwich, which scaled down manufacturing activity at the site to API manufacture only.

Cambridge, MA and Carlsbad, CA (Sept. 7)—Alnylam Pharmaceuticals and Isis Pharmaceuticals launched Regulus Therapeutics, a joint venture focused on the discovery, development, and commercialization of microRNA therapeutics. Regulus will combine the strengths and assets of Isis's and Alnylam's technologies, intellectual property, and leadership.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here